UPDATE: Needham & Company Starts STAAR Surgical (STAA) at Buy

(Updated - April 8, 2022 5:37 AM EDT)

Needham & Company analyst David Saxon initiates coverage on STAAR Surgical (NASDAQ: STAA) with a Buy rating and a price target of $87.00.

The analyst comments "We believe STAA has a clear view into durable double-digit revenue growth driven by continued international market penetration, a US EVO launch, and an OUS presbyopia ICL launch. We also believe STAA's financial model has meaningful leverage potential that could translate into strong earnings growth. We believe STAA's revenue growth and margin profiles warrant a premium multiple and, given these points, we are initiating coverage with a Buy rating and an $87 price target."

For an analyst ratings summary and ratings history on STAAR Surgical click here. For more ratings news on STAAR Surgical click here.

Shares of STAAR Surgical closed at $72.39 yesterday.

You May Also Be Interested In

• UPDATE: JPMorgan Downgrades Bath & Body Works Inc. (BBWI) to Neutral
• SATS Ltd. (SATS:SP) (SPASF) PT Lowered to SGD5 at CLSA
• UPDATE: JMP Securities Upgrades Seven Hills Realty Trust (SEVN) to Market Outperform